Neurology Medical News about psychosis Parkinson's quetiapine

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease
Neuropsychiatric Disease and Treatment, 05/28/09

Shotbolt P et al. - Quetiapine at doses of up to 150 mg/day failed to significantly improve psychosis compared to placebo, however the small sample size does not allow any conclusive interpretation of the results. Quetiapine did not appear to worsen PD motor functioning, but its use was limited by a faster drop out compared with placebo. Significant impediments were difficulty with recruitment and natural fluctuation in symptoms during the trial.

Methods

Conducted a 12 week double blind randomized placebo-controlled trial.
Time to dropout due to lack of improvement of psychosis was the primary outcome measure.
Other important secondary outcomes were evaluated using standard rating scales for PD and psychiatric symptoms.

Results

Twenty-four eligible subjects gave consent.
The primary outcome, time to dropout, was examined using survival analysis.
It was shown that patients in the quetiapine group dropped out earlier than those in the placebo group, but this difference was not significant (p = 0.68).
No significant changes were found for any of the secondary outcome measures in either group.

<< Previous
Cellular transplantation approaches for repair of the injured...

Next >>
Changes in cortical grey matter density associated with...